autoimmune diseases

Galapagos and Gilead plan to jointly develop an Ouro T cell engager for autoimmune diseases, splitting acquisition costs while Galapagos leads development and Gilead commercializes, freeing $500M in Galapagos cash.

Galapagos and Gilead are in advanced partnership talks for a first-in-class T-cell engager for autoimmune diseases, with 50% cost-sharing and €500 million capital freed for Galapagos.

Anaveon appoints veteran biotech executive Thaminda Ramanayake as CEO to guide lead candidate ANV200 through clinical development for autoimmune and inflammatory diseases.

ENAVATE deepens Zenas BioPharma stake to $142.3M. Key catalyst: obexelimab Phase 2 lupus data and Q2 2026 FDA submission.

Dianthus Therapeutics prices $625M upsized offering at $81/share to fund drug development and commercial readiness. Closing expected March 12, 2026.

Jade Biosciences reports $127.4M full-year loss, maintains $336.2M cash runway through mid-2028 with pipeline data catalysts starting Q2 2026.

Rallybio soars as merger with $505M-backed Candid Therapeutics creates combined biotech with $700M cash runway through 2030.

Danish biotech $EVAX will announce full-year 2025 financial results and business update March 5, detailing AI-Immunology platform development across oncology, infectious disease, and autoimmune applications.

Nkarta to present at two major healthcare investor conferences in March 2026, showcasing updates on its engineered NK cell therapy pipeline for autoimmune diseases.

Kyverna appoints two biotech executives to its board ahead of cell therapy commercialization. New directors bring expertise from Beam Therapeutics and Karuna Therapeutics.

Artiva Biotherapeutics appoints veteran pharma executive Thad Huston as CFO with 30+ years experience, ahead of key FDA feedback and clinical data milestones.

Eli Lilly acquires Orna Therapeutics for $2.4B to gain circular RNA gene therapy technology and autoimmune disease candidates, strengthening its pipeline.